



**UNITED STATES
NUCLEAR REGULATORY COMMISSION**

REGION III
2443 WARRENVILLE RD. SUITE 210
LISLE, IL 60532-4352

MAY 11 2017

Jason J. Wilson, R.Ph.
Radiation Safety Officer
Radiopharmacy Incorporated
1409 E. Virginia St.
Evansville, IN 47711

Dear Mr. Wilson:

This concerns your February 7, 2017 letter (ML17038A256), requesting an authorization for iodine-125 and palladium-103 seeds specifically designated for 10 CFR 35.1000 medical use. As we discussed via telephone on March 21, 2017, your NRC license No. 13-26246-01MD, as indicated in Amendment No. 21, already authorizes the requested use in Subitems 6.F. through 9.F. Based on our conversation, we understand that you have clarified the same with the manufacturer of the requested material, and have accordingly withdrawn your request. Accordingly, we have voided your request.

If you have any questions concerning this letter, please do not hesitate to call me at the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9892.

In accordance with Title 10 of the *Code of Federal Regulations* (CFR) Section 2.390, a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the Publicly Available Records component of NRC's ADAMS, which is accessible from the NRC website at <http://www.nrc.gov/reading-rm/adams.html>.

Sincerely,

A handwritten signature in cursive script that reads "Sara A. Forster".

Sara A. Forster, M.S.
Health Physicist
Materials Licensing Branch

License No. 13-26246-01MD
Docket No. 030-31910